This suggests that PDE-5 inhibitors and GC-C agonists might also be effective in treating PI-IBS or IBD patients, where the diarrhea is associated with a dysfunctional epithelial barrier rather than hypersecretion. Here, PDE5A is linked to irritable bowel syndrome.